Metformina + Vildagliptina Mylan (Metformin Hydrochloride, Vildagliptin)

Metformina + Vildagliptina is indicated for managing hyperglycemia in the type 2 diabetes mellitus pathway.

• Type 2 diabetes mellitus: improves overall glycemic control when combined with diet and exercise.
• Adjunct therapy: enhances insulin secretion and reduces hepatic glucose output in patients inadequately controlled on monotherapy.
• Combination therapy: provides a dual mechanism to lower HbA1c levels in adults with persistent hyperglycemia.

• Metformin Hydrochloride reduces hepatic gluconeogenesis and increases peripheral insulin sensitivity, thereby decreasing basal glucose production. Vildagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which prolongs the activity of incretin hormones GLP‑1 and GIP. The elevated incretins stimulate glucose‑dependent insulin release and suppress glucagon secretion, resulting in lower post‑prandial glucose excursions. Together, the two agents provide complementary actions on fasting and post‑prandial glucose.

Metformina + Vildagliptina may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea, often transient during treatment initiation.
• Headache: mild to moderate intensity, usually resolves without intervention.
• Hypoglycemia: especially when used with insulin or sulfonylureas, requiring glucose monitoring.

Serious or Rare Side Effects

• Lactic acidosis: a rare but potentially fatal metabolic complication, presenting with malaise, myalgia, and rapid breathing.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, requiring immediate discontinuation.
• Pancreatitis: inflammation of the pancreas presenting with severe abdominal pain, vomiting, and elevated enzymes.

When prescribing Metformina + Vildagliptina, clinicians should consider several precautionary measures to ensure patient safety.

• Renal function: assess baseline creatinine clearance and monitor periodically.
• Hepatic disease: use with caution in patients with liver impairment.
• Risk of lactic acidosis: avoid in severe renal insufficiency or conditions predisposing to hypoxia.
• Pregnancy and lactation: safety not established; prescribe only if potential benefit justifies risk.
• Hypoglycemia monitoring: increase vigilance when combined with other glucose‑lowering agents.
• Store at ambient temperature: keep in original container, protect from moisture and light.

Metformina + Vildagliptina can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid)

• Insulin or sulfonylureas: may cause severe hypoglycemia.
• Iodinated contrast agents: can precipitate renal impairment, increasing metformin accumulation risk.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise vildagliptin plasma levels.

Moderate Interactions (Monitor Closely)

• Diuretics: may affect renal function, requiring dose adjustment.
• ACE inhibitors or ARBs: monitor renal parameters and potassium.
• Beta‑blockers: can mask hypoglycemia symptoms, necessitating closer glucose monitoring.